← Dashboard
Oct 30, 2026 06:14 AM ET
Signal
FDA/Bio
Stoke outlines Q3 2027 EMPEROR readout and plans NDA submission in second half 2027
Stoke targets Q3 2027 EMPEROR readout and NDA submission in second half 2027.
What changed
Stoke targets Q3 2027 EMPEROR readout and NDA submission in second half 2027.
Why it matters
Stoke targets Q3 2027 EMPEROR readout and NDA submission in second half 2027. — impact context not separately stored; see What changed.
Sources
seekingalpha
Related signals
In reversal, American Cancer Society urges routine prostate cancer screening →
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →
PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →